A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus

NCT02220296 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy
Diabetes
Diabetes Mellitus, Type 1

Interventions

DRUG: Insulin 338
DRUG: placebo
DRUG: Insulin 338
DRUG: insulin glargine

Sponsor

Novo Nordisk A/S